| Literature DB >> 30538222 |
Xin Su1, Yalin Wei2, Junjie Cao3, Xiulin Wu4, Daiyong Mou1, Jinyong Luo1, Aifang Li5, Guo-Wei Zuo6, Min Tang7.
Abstract
Notch signaling pathway is one of the most important pathways to regulate intercellular signal transduction and is crucial in the regulation of bone regene<span class="Species">ration. <span class="Disease">Nephroblastoma overexpressed (NOV or CCN3) serves as a non-canonical secreted ligand of Notch signaling pathway and its role in the process of osteogenic differentiation of mesenchymal stem cells (MSCs) was undefined. Here we conducted a comprehensive study on this issue. In vivo and in vitro studies have shown that CCN3 significantly inhibited the early and late osteogenic differentiation of mouse embryonic fibroblasts (MEFs), the expression of osteogenesis-related factors, and the subcutaneous ectopic osteogenesis of MEFs in nude mice. In mechanism studies, we found that CCN3 significantly inhibited the expression of BMP9 and the activation of BMP/Smad and BMP/MAPK signaling pathways. There was also a mutual inhibition between CCN3 and DLL1, one of the classic membrane protein ligands of Notch signaling pathway. Additionally, we further found that Hey1, the target gene shared by BMP and Notch signaling pathways, partially reversed the inhibitory effect of CCN3 on osteoblastic differentiation of MEFs. In summary, our findings suggested that CCN3 significantly inhibited the osteogenic differentiation of MEFs. The inhibitory effect of CCN3 was mainly through the inhibition of BMP signaling and the mutual inhibition with DLL1, so as to inhibit the expression of Hey1, the target gene shared by BMP and Notch signaling pathways.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30538222 PMCID: PMC6289993 DOI: 10.1038/s41419-018-1234-1
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Fig. 1The basic expression of CCN3 in MEFs.
ELISA assays to determine the CCN3 protein in cell culture supernatants. The data are shown as mean ± SD for three separate experiments
Fig. 2CCN3 inhibits early and late osteogenic differentiation of MEFs.
a–d ALP staining assay (a, c) and quantitative assay (b, d) to determine the ALP activity under the treatment as shown at 3, 5, and 7 days postinfection (magnification ×100). e, f Alizarin Red S staining assay was used to assess matrix mineralization under the treatment as shown at 14 days postinfection (magnification ×100). The data are shown as mean ± SD for three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 3CCN3 inhibits the expression of osteogenic-related factors of MEFs.
a, c qRT-PCR (a) and western blot (c) were adopted to detect the effects of CCN3 on the expression of Runx2 at 3 days posttreatment. b, d qRT-PCR (b) and western blot (d) were adopted to detect the effects of siCCN3 on the expression of Runx2 at 3 days posttreatment. e, f Western blot to determine the effects of CCN3 (e) and siCCN3 (f) on the expression of OPN and OCN at 7 days posttreatment. β-Actin was used as a loading control. The data are shown as mean ± SD for three separate experiments. *P < 0.05. **P < 0.01, ***P < 0.001
Fig. 4CCN3 suppresses the subcutaneous ectopic osteogenesis of MEFs in nude mice.
a The general observation of the subcutaneous mass of ectopic osteogenesis in nude mice. b Subcutaneous osteoblast mass for micro-CT scanning to get a representative reconstructed 3D image, scaling 1 mm. c Quantitative analysis of bone tissue and the values of BV/TV, Tb.N, Tb.Sp, Tb.Th, CT, and SMI were analyzed. d H&E staining and Masson’s Trichrome staining to detect the formation of trabecular bone and bone matrix under the treatment as shown (magnification ×400). e Immunohistochemistry to verify the effects of CCN3 and siCCN3 on the expression of osteogenic-related markers (magnification ×200, ×400). The data are shown as mean ± SD for three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 5CCN3 restrains BMP9 signaling pathway.
a, b, d qRT-PCR was adopted to detect the effects of CCN3 (a), siCCN3 (b), and DLL1 (d) on the mRNA level of BMP9 at 3 days posttreatment. c qRT-PCR to detect the effects of BMP9 on the mRNA level of CCN3 at 3 days posttreatment. e–h Western blot to determine the expression of p-Smad1/5/8, Smad1/5/8, p- Erk1/2, Erk1/2, p-p38, p38, p-JNK, and JNK under the treatment as shown at 3 days postinfection. The data are shown as mean ± SD for three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 6CCN3 suppresses osteogenic differentiation of MEFs by inhibiting DLL1.
a, b qRT-PCR was adopted to detect the effects of CCN3 (a) and siCCN3 (b) on the mRNA levels of the canonical receptors and ligands of Notch signaling pathway at three days posttreatment. c, d qRT-PCR (c) and western blot (d) were used to determine the effects of DLL1 on the expression of CCN3 at 3 days posttreatment. e, f ALP staining assay (e) and quantitative assay (f) to determine the ALP activity under the treatment as shown at 7 days postinfection (magnification ×100). The data are shown as mean ± SD for three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 7CCN3 restrains osteogenic differentiation of MEFs by inhibiting Hey1.
a–c qRT-PCR was employed to measure the effects of CCN3 (a), siCCN3 (b), and DLL1 (c) on the mRNA level of Hey1 at 3 days posttreatment. d, e ALP staining assay (d) and quantitative assay (e) to determine the ALP activity under the treatment as shown at 7 days postinfection (magnification ×100). The data are shown as mean ± SD for three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 8CCN3 inhibits subcutaneous ectopic osteogenesis of MEFs in nude mice by suppressing Hey1.
a The general observation of the subcutaneous mass of ectopic osteogenesis in nude mice. b Subcutaneous osteoblast mass for micro-CT scanning to get a representative reconstructed 3D image, scaling 1 mm. c Quantitative analysis of bone tissue and the values of BV/TV, Tb.N, Tb.Sp, Tb.Th, CT, and SMI were analyzed. d H&E staining and Masson’s Trichrome staining to detect the formation of trabecular bone and bone matrix under the treatment as shown (magnification ×400). e Immunohistochemistry to determine the expression of osteogenic-related markers under the treatment as shown (magnification ×200, ×400). The data re shown as mean ± SD for three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001
Sequences of primers used for qRT-PCR (mouse)
| Primer | Forward | Reversed |
|---|---|---|
| GAPDH | GGCTGCCCAGAACATCAT | ATGATGTTCTGGGCAGCC |
| Runx2 | GGTGAAACTCTTGCCTCGTC | AGTCCCAACTTCCTGTGCT |
| CCN3 | ACGGAGAGAAGTTTGAGCCG | AGCCACAGGTCCACTTTTCG |
| BMP9 | CTGCCCTTCTTTGTTGTCTT | CCTTACACTCGTAGGCTTCATA |
| Hey1 | GGCCTGCTTGGCTTTTCT | CCAAGTGCAGGCAAGGTC |
| Notch1 | GGTGAACAATGTGGATGCTG | GCAACACTTTGGCAGTCTCA |
| Notch2 | GAGGATGAGGCTTTGCTGTC | GTTCTGCCTGAGGAGGAGTG |
| Notch3 | CTCTGTGGTGATGCTGGAGA | AATCAAGTCGCTCCACTGCT |
| Notch4 | AATCGGAGGTTCTGGATGTG | GGGTTCCAGATTTCCTAGCC |
| Jag1 | GGAAGTGGAGGAGGATGACA | GTCCAGTTCGGGTGTTTTGT |
| Jag2 | TCCGAGTACGCTGTGATGAG | GGCTTCTTTGCATTCTTTGC |
| DLL1 | CCGGCTGAAGCTACAGAAAC | AGCCCCAATGATGCTAACAG |
| DLL3 | TCTACCTCCCCCTACCGACT | CCTGATGTGGTTGAGCAAAA |
| DLL4 | CCTCTCGAACTTGGACTTGC | TGGAAATACAGATGCCCACA |